Depression and pain: Novel clinical, neurobiological and psychopharmacological data;Depresja a ból: Nowe dane kliniczne, neurobiologiczne i psychofarmakologiczne

Psychiatria Polska

Volumn 39, Issue 5, 2005, Pages 937-950

  Jaracz, Jan ^a   Rybakowski, Janusz ^a  

^a Poznan University of Medical Sciences   (Poland)

Author keywords

Antidepressant drugs; Depression; Neuroanatomy; Neurotransmission; Pain

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOPAMINE; DULOXETINE; IMIPRAMINE; MILNACIPRAN; MIRTAZAPINE; NEUROPEPTIDE; NEUROTRANSMITTER; NORADRENALIN; OPIATE; PLACEBO; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AMYGDALOID NUCLEUS; CINGULATE GYRUS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; EMOTION; FIBROMYALGIA; HUMAN; META ANALYSIS; MOOD; NEUROANATOMY; NEUROBIOLOGY; NEUROTRANSMISSION; NOCICEPTION; NORADRENERGIC SYSTEM; PAIN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PREVALENCE; PSYCHOPHARMACOLOGY; SEROTONINERGIC SYSTEM; SYMPTOM; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CENTRAL NERVOUS SYSTEM; CYCLOHEXANOLS; CYCLOPROPANES; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; MIANSERIN; PAIN; RECEPTORS, NEUROTRANSMITTER; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 28544452619     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Miȩdzynarodowa statystyczna klasyfikacja chorób i problemów zdrowotnych. Rewizja dziesia̧ta. Rozdział V: Zaburzenia psychiczne i zachowania. Kraków: Uniwersyteckie Wydawnictwo Medyczne "Vesalius", 1994.
2. Diagnostic and statistical manual of mental disorders - fourth edition (DSM-IV), Washington D.C.: American Psychiatric Association; 1994.
3. Corruble E, Guelfi JD. Pain complaints in depressed inpatients. Psychopathol. 2000; 33: 307-309.
4. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch. Gen. Psychiatry 2003; 60: 39-47.
5. Silverstein B. Gender differences in the prevalence of somatic versus pure depression: a replication. Am. J. Psychiatry 2002; 159: 1051-1052.
6. Magni G, Schifano F, De Leo D. Pain as a symptom in elderly depressed patients. Relationship to diagnostic subgroups. Eur. Arch. Psychiatry Neurol. Sc. 1985; 235: 143-5.
7. Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000; 40: 818-823.
8. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurol. 2003; 60: 1308-1312.
9. Torelli P, D'Amico D. An updated review of migraine and co-morbid psychiatric disorders. Neurol. Sc. 2004; 25, supl. 3: 234-235.
10. Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. Pain 2004; 107: 54-60.
11. Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer-type and treatment. Psychooncol. 2001; 10: 156-165.
12. Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L, Kuck J, Leslie V, Masur D, Wagner M, Waid R, Zisook S. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosom. 1999; 40: 57-63.
13. Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom. Med. 2002; 64: 52-60,
14. Proctor EK, Morrow-Howell NL, Dore P, Wentz J, Rubin EH, Thompson S, Li H. Comorbid medical conditions among depressed elderly patients discharged home after acute psychiatric care. Am. J. Geriatr. Psychiatry 2003; 11: 329-338.
15. Bruce ML, McAvay GJ, Raue PJ, Brown EL, Meyers BS, Keohane DJ, Jagoda DR, Weber C. Major depression in elderly home health care patients. Am. J. Psychiatry 2002; 159: 1367-1374.
16. Livingston G, Watkin V, Milne B, Manela MV, Katona C. Who becomes depressed? The Islington community study of older people. J. Affect. Disord. 2000; 58: 125-133.
17. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 2003; 163: 2433-2445.
18. Stahl SM. Does depression hurt? J. Clin. Psychiatry 2002; 63: 273-274.
19. Stahl SM. The psychopharmacology of painful physical symptoms in depression. J. Clin. Psychiatry 2002; 63: 382-383.
20. Stahl SM, Briley M. Understanding pain in depression. Hum. Psychopharmacol. Clin. Exp. 2004; 19: 9-13.
21. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001; 293 (5 528): 311-315.
22. Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA, Koeppe RA. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch. Gen. Psychiatry 2003; 60: 1145-1153.
23. Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects - a possible opioid involvement in severe depression? J. Mol. Neurose. 2002; 18: 143-149.
24. Mantych PW. Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiatry 2002; 63 (supl. 11): 6-10.
25. Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J. Psychiatry Neurose. 2004; 29: 208-218.
26. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacol. 2004; 29: 385-392.
27. Krishan RK. Clinical experience with substance P receptor (NK1) antagonist in depression. J. Clin. Psychiatry 2002; 63: 25-29.
28. Price DD. Central neural mechanism that interrelate sensory and affective dimension of pain. Molecular Interv. 2002; 2: 392-402.
29. Schneider F, Habel U, Holthusen H, Kessler C, Posse S, Muller-Gartner HW. Subjective ratings of pain correlate with subcortical-limbic blood flow: an fMRI study. Neuropsychobiol. 2001; 43: 175-185.
30. Bornhovd K, Quante M, Glauche V, Bromm B, Weiller C, Buchel C. Painful stimuli evoke different stimulus-response functions in the amygdala, prefrontal, insula and somatosensory cortex: a single-trial fMRI study. Brain 2002; 125: 1326-1336.
31. LeDoux JE. Emotion: clues from the brain. Ann. Rev. Psychol. 1995; 46: 209-235.
32. Abercrombie HC, Schaffer SM, Larson CL, Oakes TR, Lingren KA, Holden JE, Pearlman SB, Turski PA, Krahn DD, Benka RM, Davidson RJ. Metabolic rate in the right amygdala predicts negative affect in depressed patients. Neurorep. 1998; 9: 3301-3307.
33. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. J. Neurosc. 1992; 12: 3628-3641.
34. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur. Neuropsychopharmacol. 2002; 12: 527-544.
35. George MS, Ketter TA, Parekh PI, Horwitz B, Herscovitch P, Post RM. Brain activity during transient sadness and happiness in healthy women. Am. J. Psychiatry 1995; 152: 341-351.
36. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sedness. Am. J. Psychiatry 1999; 156: 675-682.
37. Peyron R, Garcia-Larrea L, Gregoire MC, Costes N, Convers P, Lavenne F. Haemodynamic brain responses to acute pain in humans: sensory and attentional networks. Brain 1999; 122: 1765-1780.
38. Eisenberger NI, Lieberman MD, Williams KD. Does rejection hurt? An FMRI study of social exclusion. Science 2003; 30: 2290-2292.
39. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J. Fam. Pract. 1999; 48: 980-990.
40. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl. J. Med. 1992; 326: 1250-1256.
41. Max MB. Treatment of post-herpetic neuralgia: antidepressants. Ann. Neurol. 1994; 35, supl. 1: 50-53.
42. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol. 2004; 19, supl. 1: 21-25.
43. nd Annual Meeting, December 7-11, 2003, San Juan, Puerto Rico. Scientific abstracts, s. 169.
44. Stahl SM. Preemptive analgesia: Is pain less costly when you pre-pay for it? J. Clin. Psychiatry 2004; 64: 1591-1592.
45. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann. Pharmacother. 2001; 35: 557-559.
46. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110: 697-706.
47. Kiayias JA, Vlachou ED, Lakka-Papadodima E. Venlafaxine HCl in the treatment of painful peripheral diabetic neuropathy. Diabetes Care. 2000, 23, 699.
48. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurol. 2003; 60: 1284-1289.
49. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin. Neurol. Neurosurg. 2004; 107: 44-48.
50. Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Orofac. Pain. 2004; 18: 131-137.
51. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann. Pharmacother. 2003; 37: 1561-1565.
52. Bradley RH, Barkin RL, Jerome J, DeYoung K, Dodge CW. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am. J. Ther. 2003; 10: 318-323.
53. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum. Psychopharmacol. 2004; 19, supl. 1: 27-35.
54. Tanikawa H. Efficacy of milnacipran in patients with chronic orthopaedic pain including degenerative spondylosis and osteoarthritis. Int. J. Psychiatry Clin. Pract. 2002; 6: 225-237.
55. Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J. Pharmacol. Exp. Ther. 2005; 312: 726-732.
56. Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV. Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prime care companion. J. Clin. Psychiatry 2003; 5: 19-28.
57. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry 2004; 65: 521-530.
58. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry 2002; 63: 308-315.
59. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J. Psychiatr. Res. 2005; 39: 43-53.
60. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004; 50: 2974-2984.
61. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurol. 2004; 62: 1706-1711.
62. Samborski W, Leżańska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004; 37: 168-170.
63. Rabe-Jabłońska J, Miller A. Zwia̧zki miédzy bólem a depresja̧. Psychiatr. Pol. 2005; 39: 7-20.
64. Miller A, Rabe-Jabłońska J. Skuteczność leków przeciwdepresyjnych w leczeniu bólu przewleklego nienowotworowego - przegla̧d badań. Psychiatr. Pol.: 2005; 39: 21-32.